VRTX vs. REGN

Last updated Jun 3, 2026

VRTX (Vertex Pharmaceuticals Incorporated) and REGN (Regeneron Pharmaceuticals, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 10 years, VRTX returned 16.29%/yr vs 4.25%/yr for REGN. At a 0.35 correlation, their price movements are largely independent.

Performance

VRTX vs. REGN - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Vertex Pharmaceuticals Incorporated (VRTX) and Regeneron Pharmaceuticals, Inc. (REGN). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, VRTX achieves a -6.24% return, which is significantly higher than REGN's -21.68% return. Over the past 10 years, VRTX has outperformed REGN with an annualized return of 16.29%, while REGN has yielded a comparatively lower 4.25% annualized return.

VRTX

• 1D: -3.04%
• 1M: 0.28%
• YTD: -6.24%
• 6M: -1.86%
• 1Y: -4.57%
• 3Y*: 8.39%
• 5Y*: 15.02%
• 10Y*: 16.29%

REGN

• 1D: 0.38%
• 1M: -13.91%
• YTD: -21.68%
• 6M: -18.52%
• 1Y: 23.51%
• 3Y*: -6.34%
• 5Y*: 3.75%
• 10Y*: 4.25%

*Multi-year figures are annualized to reflect compound growth (CAGR)

VRTX vs. REGN - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
VRTX Vertex Pharmaceuticals Incorporated	-6.24%	12.58%	-1.03%	40.90%	31.50%	-7.08%	7.94%	32.13%	10.58%	103.42%
REGN Regeneron Pharmaceuticals, Inc.	-21.68%	8.96%	-18.90%	21.73%	14.25%	30.72%	28.66%	0.53%	-0.65%	2.42%

Correlation

The correlation between VRTX and REGN is 0.41, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.41
Correlation (3Y) Calculated over the trailing 3-year period	0.44
Correlation (5Y) Calculated over the trailing 5-year period	0.47
Correlation (10Y) Calculated over the trailing 10-year period	0.52
Correlation (All Time) Calculated using the full available price history since Jul 25, 1991	0.35

The correlation between VRTX and REGN shifts across timeframes, from 0.35 (all time) to 0.52 (10 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap VRTX : $108.95B REGN : $64.93B
EPS VRTX : $16.87 REGN : $41.05
PE Ratio VRTX : 25.20 REGN : 14.69
PS Ratio VRTX : 8.92 REGN : 4.35
PB Ratio VRTX : 4.11 REGN : 2.07
Total Revenue (TTM) VRTX : $12.26B REGN : $14.92B
Gross Profit (TTM) VRTX : $10.57B REGN : $12.61B
EBITDA (TTM) VRTX : $5.19B REGN : $5.74B

Return for Risk

VRTX vs. REGN — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

VRTX

VRTX Risk / Return Rank: 33
VRTX Sharpe Ratio Rank: 35
VRTX Sortino Ratio Rank: 31
VRTX Omega Ratio Rank: 31
VRTX Calmar Ratio Rank: 35
VRTX Martin Ratio Rank: 33

REGN

REGN Risk / Return Rank: 61
REGN Sharpe Ratio Rank: 63
REGN Sortino Ratio Rank: 58
REGN Omega Ratio Rank: 57
REGN Calmar Ratio Rank: 60
REGN Martin Ratio Rank: 68

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

VRTX vs. REGN - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Vertex Pharmaceuticals Incorporated (VRTX) and Regeneron Pharmaceuticals, Inc. (REGN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	VRTX	REGN	Difference
Sharpe ratio Return per unit of total volatility	-0.14	0.72	-0.86
Sortino ratio Return per unit of downside risk	0.05	1.23	-1.18
Omega ratio Gain probability vs. loss probability	1.01	1.15	-0.14
Calmar ratio Return relative to maximum drawdown	-0.16	0.91	-1.08
Martin ratio Return relative to average drawdown	-0.35	3.30	-3.65
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

VRTX vs. REGN - Sharpe Ratio Comparison

The current VRTX Sharpe Ratio is -0.14, which is lower than the REGN Sharpe Ratio of 0.72. The chart below compares the historical Sharpe Ratios of VRTX and REGN, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	VRTX	REGN	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.14	0.72	-0.86
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.52	0.12	+0.40
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.50	0.13	+0.37
Sharpe Ratio (All Time) Calculated using the full available price history	0.25	0.16	+0.10

Drawdowns

VRTX vs. REGN - Drawdown Comparison

The maximum VRTX drawdown since its inception was -91.77%, roughly equal to the maximum REGN drawdown of -91.81%. Use the drawdown chart below to compare losses from any high point for VRTX and REGN.

Drawdown Indicators

	VRTX	REGN	Difference
Max Drawdown Largest peak-to-trough decline	-91.77%	-91.81%	+0.04%
Max Drawdown (1Y) Largest decline over 1 year	-23.56%	-25.85%	+2.29%
Max Drawdown (3Y) Largest decline over 3 years	-29.07%	-59.69%	+30.62%
Max Drawdown (5Y) Largest decline over 5 years	-29.07%	-59.69%	+30.62%
Max Drawdown (10Y) Largest decline over 10 years	-41.60%	-59.69%	+18.09%
Current Drawdown Current decline from peak	-17.74%	-49.42%	+31.68%
Average Drawdown Average peak-to-trough decline	-37.70%	-42.38%	+4.68%
Ulcer Index Depth and duration of drawdowns from previous peaks	11.11%	7.16%	+3.95%

Volatility

VRTX vs. REGN - Volatility Comparison

The current volatility for Vertex Pharmaceuticals Incorporated (VRTX) is 7.13%, while Regeneron Pharmaceuticals, Inc. (REGN) has a volatility of 12.02%. This indicates that VRTX experiences smaller price fluctuations and is considered to be less risky than REGN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	VRTX	REGN	Difference
Volatility (1M) Calculated over the trailing 1-month period	7.13%	12.02%	-4.89%
Volatility (6M) Calculated over the trailing 6-month period	21.76%	22.49%	-0.73%
Volatility (1Y) Calculated over the trailing 1-year period	33.88%	32.72%	+1.16%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	28.90%	30.75%	-1.85%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	32.83%	32.16%	+0.67%

Dividends

VRTX vs. REGN - Dividend Comparison

VRTX has not paid dividends to shareholders, while REGN's dividend yield for the trailing twelve months is around 0.60%.

Position	TTM	2025
REGN Regeneron Pharmaceuticals, Inc.	0.60%	0.46%
VRTX Vertex Pharmaceuticals Incorporated	0.00%	0.00%

Financials

VRTX vs. REGN - Profitability Comparison

The chart below illustrates the profitability comparison between Vertex Pharmaceuticals Incorporated and Regeneron Pharmaceuticals, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

VRTX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Vertex Pharmaceuticals Incorporated reported a gross profit of 2.59B and revenue of 2.99B. Therefore, the gross margin over that period was 86.9%.

REGN - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Regeneron Pharmaceuticals, Inc. reported a gross profit of 2.94B and revenue of 3.61B. Therefore, the gross margin over that period was 81.4%.

VRTX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Vertex Pharmaceuticals Incorporated reported an operating income of 1.14B and revenue of 2.99B, resulting in an operating margin of 38.1%.

REGN - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Regeneron Pharmaceuticals, Inc. reported an operating income of 642.90M and revenue of 3.61B, resulting in an operating margin of 17.8%.

VRTX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Vertex Pharmaceuticals Incorporated reported a net income of 1.03B and revenue of 2.99B, resulting in a net margin of 34.5%.

REGN - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Regeneron Pharmaceuticals, Inc. reported a net income of 727.20M and revenue of 3.61B, resulting in a net margin of 20.2%.

Frequently Asked Questions

Can I hold both VRTX and REGN in my portfolio?

VRTX and REGN have a correlation of 0.41, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, VRTX or REGN?

REGN has higher volatility (12.02%) compared to VRTX (7.13%). In terms of maximum drawdown, VRTX dropped -91.77% vs REGN's -91.81%.

Which has better risk-adjusted returns?

REGN currently has the higher Sharpe Ratio (0.72 vs -0.14), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.